Whole abdominal irradiation following chemotherapy in advanced ovarian carcinoma

Kuten, Abraham; Stein, Moshe; Steiner, Mariana; Rubinov, R.; Epelbaum, Ron; Cohen, Yoram

doi:10.1016/0360-3016(88)90432-4

Cited by 36 publications

(24 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Negative outcomes are reported in a number of these studies (5,(26)(27)(28)31,33) . More promising results are presented by others (10)(11)(12)14,29,30,32) , even though most series are small and not randomized. Complete surgical but not pathologic remission after induction chemotherapy.…”

Section: Discussionmentioning

confidence: 95%

“…Consolidation radiotherapy has been evaluated in a number of reports during the past decade (5,(10)(11)(12)14,(26)(27)(28)(29)(30)(31)(32)(33) . Negative outcomes are reported in a number of these studies (5,(26)(27)(28)31,33) .…”

Section: Discussionmentioning

confidence: 99%

“…Whole abdominal radiotherapy has also been used as consolidation treatment after primary surgery and induction chemotherapy (5,(26)(27)(28)(29)(30)(31)(32) . Prerequisites for successful treatment with minimal morbidity were proposed by Thomas in 1993 (10) .…”

mentioning

confidence: 99%

“…Prerequisites for successful treatment with minimal morbidity were proposed by Thomas in 1993 (10) . A possible benefit of this treatment option has been noted for patients with tumors in complete pathologic remission or with minimal residual disease (32) . Acute hematologic toxicity (27,32) and delayed intestinal side effects are reported to be significant problems in some trials.…”

mentioning

confidence: 99%

“…A possible benefit of this treatment option has been noted for patients with tumors in complete pathologic remission or with minimal residual disease (32) . Acute hematologic toxicity (27,32) and delayed intestinal side effects are reported to be significant problems in some trials. A lack of randomized and controlled trials has prevented drawing firm conclusions about the value of radiotherapy for this group of patients (31) .…”

mentioning

confidence: 99%

See 4 more Smart Citations

Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: A randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment

SORBE

2003

Int J Gynecol Cancer

View full text Add to dashboard Cite

In a prospective randomized trial, consolidation treatment with radiotherapy or chemotherapy was compared with no treatment in a series of 172 patients with epithelial ovarian carcinoma, FIGO stage III, with complete surgical remission after primary cytoreductive surgery and induction chemotherapy. In the subgroup with complete surgical and pathologic remission, progression-free survival was significantly (P= 0.032) better in the radiotherapy group (56% at 5 years) than in the chemotherapy group (36% at 5 years) and the untreated control group (35% at 5 years). Overall survival was also most favorable in the radiotherapy group (69% at 5 years). The number of recurrences was lowest in the radiotherapy group. In the subgroup with microscopic residual carcinoma there were no significant differences in survival between the radiotherapy and the chemotherapy-treated patients. Early and late radiation reactions were recorded. Treatment-related side effects were seen most frequently in the radiotherapy group. Late intestinal radiation reactions of a severe type were recorded in 10%.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: A randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment

SORBE

2003

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

Consolidative32P after second-look laparotomy for ovarian carcinoma

Condra

Mendenhall

Morgan

et al. 1998

Radiat. Oncol. Investig.

View full text Add to dashboard Cite

We report our experience with consolidative 32P after second‐look laparotomy. Forty‐three patients received consolidative 32P after platinum‐based chemotherapy and a negative (39 patients, 91%) or positive (4 patients) second‐look laparotomy. Thirty‐one patients (72%) initially had stage III (30 patients) or stage IV (1 patient) disease; 28 patients (65%) had grade 3 tumors. Patients had follow‐up from 3.5 to 14.9 years (median, 7.7 years); no patient was lost to follow‐up. The 5‐year rates of control of disease within the abdomen (local control) for the overall group and the subset of patients with stage II‐IV disease and a negative second‐look laparotomy were 65% and 69%, respectively. The corresponding 5‐year survival rates were 78 and 81%, respectively. Multivariate analyses revealed that tumor found at second‐look laparotomy significantly influenced the likelihood of local control and cause‐specific survival. Acute side effects included cellulitis (1 patient) and ileus (3 patients). Two patients (5%) experienced severe late complications; both experienced small bowel obstruction that necessitated surgical intervention. Consolidative 32P appears to reduce the risk of recurrence and improve survival after negative second‐look laparotomy. The risk of significant complications is low. Radiat. Oncol. Invest. 6:97–102, 1998. © 1998 Wiley‐Liss, Inc.

show abstract

Consolidative 32P after second‐look laparotomy for ovarian carcinoma

Condra

Mendenhall

Morgan

et al. 1998

Radiat. Oncol. Investig.

View full text Add to dashboard Cite

SUMMARY We report our experience with consolidative 32 P after second-look laparotomy. Forty-three patients received consolidative 32 P after platinum-based chemotherapy and a negative (39 patients, 91%) or positive (4 patients) second-look laparotomy. Thirtyone patients (72%) initially had stage III (30 patients) or stage IV (1 patient) disease; 28 patients (65%) had grade 3 tumors. Patients had follow-up from 3.5 to 14.9 years (median, 7.7 years); no patient was lost to follow-up. The 5-year rates of control of disease within the abdomen (local control) for the overall group and the subset of patients with stage II-IV disease and a negative second-look laparotomy were 65% and 69%, respectively. The corresponding 5-year survival rates were 78 and 81%, respectively. Multivariate analyses revealed that tumor found at second-look laparotomy significantly influenced the likelihood of local control and cause-specific survival. Acute side effects included cellulitis (1 patient) and ileus (3 patients). Two patients (5%) experienced severe late complications; both experienced small bowel obstruction that necessitated surgical intervention. Consolidative 32 P appears to reduce the risk of recurrence and improve survival after negative second-look laparotomy. The risk of significant complications is low.

show abstract

Whole abdominal irradiation following chemotherapy in advanced ovarian carcinoma

Cited by 36 publications

References 15 publications

Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: A randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment

Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: A randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment

Consolidative32P after second-look laparotomy for ovarian carcinoma

Consolidative 32P after second‐look laparotomy for ovarian carcinoma

Contact Info

Product

Resources

About